Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the body's own defences to attack cancer," said Ken Takeshita, the Japanese ...

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...

Companies don’t generally cut prices out of generosity.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up ...

The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

Launching next year, the new CMS Innovation Center initiative—known as the GENEROUS Model—aims to align Medicaid drug prices ...

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.